Back to search results

DIVERSE Study: Improving Clinical Trial Inclusion for Blood Cancer

This study, called DIVERSE, aims to make clinical trials more inclusive and diverse. It tests a new system where patients and community members review and give feedback on research plans for future clinical trials. You could join if you are 18 or older, speak English, and can give consent. People who have been in remission from blood cancer for over a year are preferred. The study will be successful if many reviews are completed, especially within 35 days, and if participants find the DIVERSE process acceptable. The current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 40 participants. It involves a community-based review system for clinical research protocols.
What's involved
Participation in this research is expected to last about 18 months. You would complete specialized training and provide feedback on clinical trials and the DIVERSE process itself.
Compensation
Not stated in the trial record.
Follow-up
The primary goals of the study are measured at 18 months, indicating the duration of observation for the intervention's effectiveness.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06469307

Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)

Recruiting
NAAges 18+InterventionalHealth services
Dana-Farber Cancer Institute
~40 participants
Updated 2026-07-16 on ClinicalTrials.gov
What's tested:DIVERSE Review Process

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Protocol Review Completion Rate
Measured over 18 months
+2 more outcomes measured

Conditions

Blood Cancer
Leukemia

Explore related trials

LeukemiaLiquid Tumor

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Andrew Hantel, MD · PRINCIPAL_INVESTIGATOR · Dana-Farber Cancer Institute

Who to contact

Andrew Hantel, MD
[email protected]
617-582-9394
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 or older
English speaking
Ability to understand and willingness to provide oral consent
DFCI patient who are in remission from a blood cancer \>1 year will be preferred.
Age 18 older
English Speaking
Site or Principal investigator
Not a member of the research team

Exclusion

Adults unable to consent
Individuals who are not yet adults (infants, children, teenagers \<18 years old)
Prisoners.
Unwilling/unable to agree to maintaining the confidentiality of reviews and clinical trial materials, as outlined in Section 9.1
Note 1: Patients and non-patient community members who are pregnant are eligible. This is a non-interventional study that meets the definition of minimal risk and poses no greater risk to pregnant individuals or fetuses. Pregnancy status will not be assessed.
Note 2: English fluency is necessary as protocols being reviewed are written in English and cannot be feasibly translated to other languages within the time period necessary to complete timely reviews.

What this trial measures

  • Protocol Review Completion Rate18 months

    Feasibility is defined as the proportion of eligible protocols that have completed the DIVERSE review process. The target is a review completion of ≥ 60% of eligible protocols.

  • Protocol Review Completion Rate Within 35 Days18 months

    Feasibility is defined as the proportion of protocols that have completed the DIVERSE review process within 35 days of request. The goal is to have ≥ to 70% of reviews completed within 35 days.

  • Proportion of Acceptability of Intervention Measure (AIM) Scores of 10 or Greater18 months

    Acceptability is defined as the proportion of AIM scores provided by investigators after protocols have been assessed by the DIVERSE review process with ≥ 60% of AIM scores resulting as ≥10 on a scale of 0 - 20, where scores of 10 or above are considered "acceptable" or greater. The AIM is a 4-item, 5-point Likert scale-based measure.